856417-64-6

Usage

Uses

Used in Pharmaceutical Industry:
2-(tert-butoxycarbonylamino)-4-methoxy-4-oxobutanoic acid is used as a key intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for versatile chemical modifications, facilitating the design of innovative and effective medications.
Used in Bioactive Compounds Synthesis:
In the field of biochemistry, 2-(tert-butoxycarbonylamino)-4-methoxy-4-oxobutanoic acid is utilized as a precursor in the synthesis of bioactive compounds. Its incorporation into these compounds can enhance their biological activity and potential applications in medicine and healthcare.
Used in Research and Development:
2-(tert-butoxycarbonylamino)-4-methoxy-4-oxobutanoic acid is employed as a subject of study in research and development within the realms of chemistry and biochemistry. Scientists investigate its properties and explore its potential uses in a variety of applications, including drug discovery and the development of new materials and technologies.
Used in Drug Discovery and Development:
2-(tert-butoxycarbonylamino)-4-methoxy-4-oxobutanoic acid plays a significant role in drug discovery and development, where it is used as a building block to create novel drug candidates. Its unique chemical structure allows for the design of molecules with specific therapeutic targets, potentially leading to the development of new treatments for various diseases and conditions.

Upstream product

• 1835-51-4 (RS)-2-amino-3-methoxycarbonylpropionic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 129902-07-4 aspartic acid methyl ester hydrochloride 
• 67-56-1 methanol 

Downstream Products

• 2703745-95-1 methyl 3-(t-butoxycarbonylamino)-3-cyanopropanoate 
• 942297-60-1 DL-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid methyl ester 

Relevant academic research and scientific papers

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in?vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.

Heteroarylpyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5 and R6 are as defined in the specification or a pharmaceutically acceptable salt or solvate thereof, compositions thereof,

A convenient and rapid method for the selective oxygen-17 enrichment of aspartyl peptides during solid-phase synthesis

In this work we describe, for the first time, a rapid and efficient method for 17O selective labeling on the β-carboxyl group of an aspartic acid residue already incorporated into a peptide sequence anchored on a solid-phase support. The β-O-benzyl ester of the Asp residue of the Ac-RGD-benzydrylamine resin was successfully saponified using Na17OH in a methanol/dichloromethane mixture. The 17O selective enriched peptide was then released from the solid support by acidic cleavage. The 17O NMR spectrum confirmed the 17O labeling of the Asp β-carboxylate.